Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.Research Editor
jeffhans@uab.edu | (205) 209-2355Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.
Specific beats:
- Alabama Drug Discovery Alliance
- Biochemistry and Molecular Genetics
- Biomatrix Engineering and Regenerative Medicine
- Cell biology
- Center for Biophysical Sciences and Engineering
- CCTS
- Center for Metabolic Bone Disease
- Microbiology
- Neurobiology
- Comprehensive Neuroscience Center
- Pathology, research shared with MS2
- Pharmacology and Toxicology
- Physiology and Biophysics
- UAB Research Foundation/IIE
- Research Administration
Nearly all of the 344 residents in Panola, Alabama, received vaccination shots.
This novel mode of altering gene silencing boosts the unfolded protein response pathway in the cancer cells, helping those cells survive during rapid growth.
For just the third time in history, a University of Alabama at Birmingham faculty member has been elected to the prestigious National Academy of Sciences.
This therapy, using sustained release of nitric oxide, may be a novel, efficient and safe way to prevent and treat multiple metabolic diseases.
An absence of sub-strain variation over a short period was seen in sick patients, which may signal impending gut dysbiosis.
This study included three lines of human cancer cells and suggests new potential therapeutic targets in cancer.
The distinct cell populations were identified by single-nucleus RNA sequencing of 21,600 cells of the rat ventral tegmental area, located in the midbrain.
Researchers show how two types of immune cells — one a part of the innate immune system and the other a part of the adaptive immune system — play distinct and indispensable roles in the colon to defend against pathogenic bacteria.
Researchers have been awarded a $2.6 million, four-year National Institutes of Health grant to evaluate a safer and more durable stent design, using techniques licensed through the UAB Harbert Institute for Innovation and Entrepreneurship by the UAB spinoff company Endomimetics LLC.
The monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness, potentially lasting a year or more when used in humans.